Items Tagged ‘KEYNOTE-028’

December 7th, 2017

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available


The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare & Medicaid Services (CMS) the latter proposed coverage of the F1CDx test under the new […]

View full entry

Tags: biomarker testing, CMS, foundation medicine, General, genomic testing, immunotherapy, KEYNOTE-028, News, Other News Topics (not Types of Cancer), PD-L1 positive, Precision Cancer Medicine, SCLS

December 27th, 2016

Keytruda® Active in Small Cell Lung Cancer


Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, SCLC accounts for 10-20% of all lung cancers. Although progress […]

View full entry

Tags: Extensive Lung Cancer - Small Cell, General Lung Cancer, immunotherapy, KEYNOTE-028, Lung Cancer, Lung Cancer - Small Cell, News, PD-L1 positive, SCLS, small cell lung cancer